Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6826053 | Schizophrenia Research | 2013 | 6 Pages |
Abstract
Although the rate of antipsychotic prescription among high-risk youth may have fallen slightly, the nearly one-in-five rate in the second cohort still constitutes a significant exposure. Mitigating factors were that doses and durations of treatment were low. As for other nonpsychotic conditions, it is incumbent on our field to develop alternative treatments for high-risk patients and to generate additional evidence for or against the efficacy of antipsychotics to help define their appropriate role if alternative treatments fail.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Scott W. Woods, Jean Addington, Carrie E. Bearden, Kristin S. Cadenhead, Tyrone D. Cannon, Barbara A. Cornblatt, Daniel H. Mathalon, Diana O. Perkins, Larry J. Seidman, Ming T. Tsuang, Elaine F. Walker, Thomas H. McGlashan,